COVID-19: Yokohama City University, Neutralizing Antibody Survey of Mutant Strains: Pfizer Vaccine Effective
Yokohama City University:
Yokohama City University conducted a neutralizing antibody survey of COVID-19 mutant strains.
It was found that “about 90% of people who received the Pfizer vaccine” “have neutralizing antibodies against the mutant strain of the new corona”.
Blood is collected after inoculation:
At Yokohama City University
For 105 people who received the Pfizer vaccine
Two weeks after the first inoculation and
Blood was collected the week after the second inoculation.
Investigate 8 strains:
The conventional “Wuhan type” and
British type of mutant strain,
Indian type of mutant strain, etc.
We investigated “whether neutralizing antibodies that prevent infection have been established for 8 strains”.
Established neutralizing antibody:
After the first inoculation, there was variability in the establishment of neutralizing antibodies.
However, after the second vaccination, “89% of people had established neutralizing antibodies against all eight strains.”
Yokohama City University: Professor Yamanaka
“We can expect very much about the establishment of herd immunity,” he said.
Professor Yamanaka:
“More than 90% of people had neutralizing antibodies” is considered to be “a promising result for herd immunity.”
Existing vaccines can be used to cope with the mutations in the current peplomer protein.
In the future, we will continue to investigate whether the vaccine is effective even after half a year or a year.
The research technology developed by Yokohama City University
Transferring know-how to a private institution,
I also want to prepare for the investigation of new mutant strains.
tvk NEWS WALL | Channel OPEN YOKOHAMA
https://www.tvk-kaihouku.jp/news_wall/post-8039.php
Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera
Abstract
The uncontrolled spread of the COVID-19 pandemic has led to the emergence of different SARS-CoV-2 variants across the globe.
The ongoing global vaccination strategy to curtail the COVID-19 juggernaut, is threatened by the rapidly spreading Variants of Concern (VOC) and other regional mutants, which are less responsive to neutralization by infection or vaccine derived antibodies.
We have previously developed the hiVNT system which detects SARS-CoV-2 neutralizing antibodies in sera in less than three hours.
In this study, we modify the hiVNT for rapid qualitative screening of neutralizing antibodies (nAb) to multiple variants of concern (VOC) of SARS-CoV-2,
and assess the neutralizing efficacy of the BNT162b2 mRNA vaccine on seven epidemiologically relevant SARS-CoV-2 variants.
Here we show that the BNT162b2 mRNA vaccine can activate humoral immunity against the major SARS-CoV-2 mutants that are currently in circulation.
Albeit a small sample size, we observed that one dose of vaccine was sufficient to elicit a protective humoral response in previously infected people.
Using a panel of seven SARS-CoV-2 variants and a single prototype virus,
our modified hiVNT would be useful for large-scale community wide testing to detect protective immunity that may confer vaccine/immune passport in the ongoing COVID-19 pandemic.
https://www.medrxiv.org/content/10.1101/2021.05.06.21256788v1